Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients with devastating diseases by developing and commercializing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics. Their proprietary EEV platform is designed to enable the intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, with an initial focus on neuromuscular diseases. Entrada's lead product candidate, ENTR-601-44, is in clinical development for patients with Duchenne muscular dystrophy (DMD) who are exon 44 skipping amenable. They are also advancing a pipeline of other EEV-based programs for neuromuscular and other diseases.
Primary hub for research and development, clinical operations, and corporate administration, driving the company's mission to develop EEV-based therapeutics.
Modern, state-of-the-art laboratory and office facilities designed to foster collaboration and innovation in a prime biotech location.
A dynamic and science-focused environment encouraging collaboration, innovation, and a strong commitment to addressing unmet patient needs. Employees often experience a fast-paced setting typical of growth-stage biotechnology companies focused on groundbreaking science.
Strategically located in Boston's Seaport District, a vibrant biotechnology hub, providing access to leading talent, research institutions, and potential collaborators. Its presence here underscores its commitment to cutting-edge science and development.
While headquartered and primarily operating its research and development in Boston, USA, Entrada Therapeutics has a global outlook. Its clinical trial operations for its therapeutic candidates, such as ENTR-601-44 for Duchenne muscular dystrophy, are designed to include international sites. The company aims to address diseases affecting patients worldwide and engages with global regulatory authorities and potential partners to advance its mission.
22 Boston Wharf Road, 7th Floor
Boston
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Entrada Therapeutics' leadership includes:
Entrada Therapeutics has been backed by several prominent investors over the years, including:
In the past 12 months, Entrada Therapeutics significantly strengthened its executive leadership team with several key appointments in August 2023, including a new Chief Medical Officer, Chief Financial Officer, Chief People Officer, and Chief Legal Officer, alongside the promotion of its Chief Operating Officer. No major executive departures were publicly announced during this period.
Discover the tools Entrada Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Entrada Therapeutics likely uses common corporate email formats. The most probable patterns are [firstinitial][last]@entradatx.com or [first].[last]@entradatx.com. For example, an employee named Jane Doe might have an email address like jdoe@entradatx.com or jane.doe@entradatx.com.
[firstinitial][last]@entradatx.com (e.g., jdoe@entradatx.com), [first].[last]@entradatx.com (e.g., jane.doe@entradatx.com)
Format
jdoe@entradatx.com
Example
80%
Success rate
GlobeNewswire • February 27, 2024
Entrada Therapeutics announced its financial results for Q4 and full year 2023, highlighting progress with its EEV-therapeutics pipeline, including updates on the Phase 1 clinical trial for ENTR-601-44 in Duchenne muscular dystrophy and plans for its myotonic dystrophy type 1 program....more
GlobeNewswire • January 4, 2024
The company announced the dosing of the first participant in its Phase 1 clinical trial (MAVERICK) of ENTR-601-44, an EEV-conjugated phosphorodiamidate morpholino oligomer (PMO) for Duchenne muscular dystrophy patients amenable to exon 44 skipping....more
GlobeNewswire • November 9, 2023
Entrada reported its Q3 2023 financial results, noting the U.S. FDA clearance of the Investigational New Drug (IND) application for ENTR-601-44 and providing updates on its research pipeline and corporate strategy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Entrada Therapeutics, are just a search away.